Blockchain technology has gained considerable attention, with an escalating interest in a plethora of numerous applications, ranging from data management, financial services, cyber security, IoT, and food science to healthcare industry and brain research. There has been a remarkable interest witnessed in utilizing applications of blockchain for the delivery of safe and secure healthcare data management. Also, blockchain is reforming the traditional healthcare practices to a more reliable means, in terms of effective diagnosis and treatment through safe and secure data sharing. In the future, blockchain could be a technology that may potentially help in personalized, authentic, and secure healthcare by merging the entire real-time clinical data of a patient’s health and presenting it in an up-to-date secure healthcare setup. In this paper, we review both the existing and latest developments in the field of healthcare by implementing blockchain as a model. We also discuss the applications of blockchain, along with the challenges faced and future perspectives.
Single-cell proteomics can reveal cellular phenotypic heterogeneity and cell-specific functional networks underlying biological processes. Here, we present a streamlined workflow combining microfluidic chips for all-in-one proteomic sample preparation and data-independent acquisition (DIA) mass spectrometry (MS) for proteomic analysis down to the single-cell level. The proteomics chips enable multiplexed and automated cell isolation/counting/imaging and sample processing in a single device. Combining chip-based sample handling with DIA-MS using project-specific mass spectral libraries, we profile on average ~1,500 protein groups across 20 single mammalian cells. Applying the chip-DIA workflow to profile the proteomes of adherent and non-adherent malignant cells, we cover a dynamic range of 5 orders of magnitude with good reproducibility and <16% missing values between runs. Taken together, the chip-DIA workflow offers all-in-one cell characterization, analytical sensitivity and robustness, and the option to add additional functionalities in the future, thus providing a basis for advanced single-cell proteomics applications.
Despite advancements of data-independent acquisition mass spectrometry (DIA-MS) to provide comprehensive and reproducible proteome profiling, its utility in very low-input samples is limited. Due to different proteome complexities and corresponding peptide ion abundances, the conventional LC−MS/MS acquisition and widely used large-scale DIA libraries may not be suitable for the micro-nanogram samples. In this study, we report a sample size-comparable library-based DIA approach to enhance the proteome coverage of low-input nanoscale samples (i.e., nanogram cells, ∼5−50 cells). By constructing sample sizecomparable libraries, 2380 and 3586 protein groups were identified from as low as 0.75 (∼5 cells) and 1.5 ng (∼10 cells), respectively, highlighting one of the highest proteome coverage with good reproducibility (86%−99% in triplicate results). For the 0.75 ng sample (∼5 cells), significantly superior identification (2380 proteins) was achieved by small-size library-based DIA, compared to 1908, 1749, and 107 proteins identified from medium-size and large-size libraries and a lung cancer resource spectral library, respectively. A similar trend was observed using a different instrument and data analysis pipeline, indicating the generalized conclusion of the approach. Furthermore, the small-size library uniquely identified 518 (22%) proteins in the low-abundant region and spans over a 5-order dynamic range. Spectral similarity analysis revealed that the fragmentation ion pattern in the DIA-MS/MS spectra of the dataset and spectral library play crucial roles for mapping low abundant proteins. With these spectral libraries made freely available, the optimized library-based DIA strategy and DIA digital map will advance quantitative proteomics applications for mass-limited samples.
In this paper, an extended review analysis has been presented concerning the developments in brain drug delivery through new and efficient applications of nanotechnology. Modern nanotechnological approaches for the diagnosis and treatment of Alzheimer's and Parkinson's diseases are described along with simultaneous analysis of safety and practical clinical usage of these strategies.
This article covers exciting developments of recent microfluidics-based single-cell proteomics methods and their utilizations to tackle important biological questions for both basic and translational research.
Image segmentation is one of the most trending fields in the domain of digital image processing. For years, researchers have shown a remarkable progress in the field of Image Segmentation, precisely, for brain tumor extraction from various medical imaging modalities including X-Ray, Computed Tomography and most importantly, Magnetic Resonance Images (MRI). In these medical imaging modalities, accurate and reliable brain tumor segmentation is extremely imperative to perform safe diagnose, healthy treatment planning and consistent treatment outcome evaluation in order to understand and cure the complexities of chronic diseases such as Cancer. This paper presents various image processing techniques that are currently being used for brain tumor extraction from medical images. Though some great work has been done in this domain but none of the techniques has been widely accepted to be brought into practice in real time clinical analysis. The paper concludes with proposing some solutions that would aid in refining the results of the techniques which will lead to clinical acceptance of these computer aided methods.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.